SCHEMBL17799693

SCHEMBL17799693

O=C(N[C@H]1CC[C@H]1c1ccc(F)cc1F)c1ccccc1C(F)(F)F

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ TAS1R3 Q7RTX0 2/20 0.47
▸ TAS1R1 Q7RTX1 2/20 0.47
▸ TAS1R2 Q8TE23 2/20 0.47
▸ HCRTR1 O43613 2/20 0.46
▸ LMNA P02545 1/20 0.44
▸ GAA P10253 1/20 0.44
▸ PTGS1 P23219 1/20 0.44
▸ PPIA P62937 1/20 0.42
▸ KCNK3 O14649 2/20 0.41
▸ KCNK9 Q9NPC2 2/20 0.41
▸ TP53 P04637 1/20 0.39
▸ HCRTR2 O43614 1/20 0.39
▸ MC1R Q01726 1/20 0.39
▸ PTGES O14684 3/20 0.39
▸ RXFP1 Q9HBX9 1/20 0.38
▸ DPP4 P27487 2/20 0.38
▸ DPP7 Q9UHL4 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17799692 0.87 HCRTR1 (0.49) TAS1R3TAS1R1TAS1R2HCRTR1LMNA
SCHEMBL16392371 0.85 TAS1R3 (0.51) TAS1R3TAS1R1TAS1R2HCRTR1LMNA
SCHEMBL19771732 0.85 TAS1R3 (0.51) TAS1R3TAS1R1TAS1R2HCRTR1LMNA
SCHEMBL17799656 0.84 HCRTR1 (0.50) TAS1R3TAS1R1TAS1R2HCRTR1HCRTR2
SCHEMBL17799707 0.84 SIGMAR1 (0.42) TAS1R3TAS1R1TAS1R2HCRTR1PPIA
SCHEMBL17799733 0.84 HCRTR1 (0.50) TAS1R3TAS1R1TAS1R2HCRTR1LMNA
SCHEMBL17799748 0.84 NPC1 (0.44) TAS1R3TAS1R1TAS1R2HCRTR1LMNA
SCHEMBL19775167 0.84 HCRTR1 (0.46) HCRTR1MC1R
SCHEMBL16371864 0.84 HCRTR1 (0.46) HCRTR1MC1R
SCHEMBL17598751 0.83 HCRTR1 (0.52) TAS1R3TAS1R1TAS1R2HCRTR1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE50724-E1 4-membered ring carboxamides used as nematicides SYNGENTA CROP PROTECTION AG (CH) 2026-01-06 — — US disclosed
EP-3019476-B1 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES SYNGENTA PARTICIPATIONS AG (CH) 2018-01-17 — — EP disclosed
US-9867371-B2 4-membered ring carboxamides used as nematicides SYNGENTA PARTICIPATIONS AG (CH) 2018-01-16 — — US disclosed
US-9867371-B2 4-membered ring carboxamides used as nematicides SYNGENTA PARTICIPATIONS AG (CH) 2018-01-16 — — US disclosed
US-20160157485-A1 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES SYNGENTA PARTICIPATIONS AG (CH) 2016-06-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160157485-A1 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES TUBA3C, DDT, CYCS TAS1R3 3195/4885TAS1R1 3418/4885TAS1R2 2989/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback